Doherty D C, Ortel T L, de Bruijn N, Greenberg C S, Van Trigt P
Department of Anesthesiology, Heart Center, Durham, North Carolina.
Anesthesiology. 1990 Sep;73(3):562-5.
Org 10172 provided adequate anticoagulation for this patient. An excellent correlation between anti-factor Xa activity and ACT was observed at the doses used for CPB. If high-dose Org 10172 is used, these data suggest that it may be possible to circumvent the measurement of anti-factor Xa activity by using the ACT as an index of this heparinoid's anticoagulant effect. Because postoperative bleeding may be excessive, however, development of a method of reversal of Org 10172 is desirable. Although the optimal ACT, dose, plasma concentration, and means of reversal (e.g., protamine vs. heparinase) remains to be determined, heparinoids provide an alternate means of anticoagulation for CPB in patients unable to receive standard heparin.
Org 10172为该患者提供了充分的抗凝作用。在用于体外循环的剂量下，观察到抗Xa因子活性与活化凝血时间（ACT）之间具有良好的相关性。这些数据表明，如果使用高剂量的Org 10172，有可能通过将ACT作为这种类肝素抗凝效果的指标来避免对抗Xa因子活性的测定。然而，由于术后出血可能过多，因此需要开发一种逆转Org 10172作用的方法。尽管最佳的ACT、剂量、血浆浓度以及逆转方法（例如，鱼精蛋白与肝素酶）仍有待确定，但类肝素为无法接受标准肝素的患者提供了一种用于体外循环抗凝的替代方法。
